ZIYOND PHARMA Submits Main Board Listing Application to HKEX; Ranks No.1 in China for Number of Filed & Approved Topical Dermatological Drugs

NewTimeSpace · 2026/07/09 16:36 · By Zehong Cheng

NewTimeSpace News: Ziyond Pharmaceutical Co., Ltd. filed a Main Board listing application with HKEX on 9 July, with CITIC Securities acting as the sole sponsor. According to Frost & Sullivan, the Company ranks first in China in terms of the total number of filed and approved topical dermatological medicines, and its commercialised products cover eight major dermatological indications in China.

NewTimeSpace News: As disclosed by HKEX, Ziyond Pharmaceutical Co., Ltd. submitted a Main Board listing application to The Stock Exchange of Hong Kong Limited on 9 July 2026, with CITIC Securities appointed as the sole sponsor.

Ziyond Pharmaceutical is a Chinese pharmaceutical enterprise focusing on topical dermatology, delivering comprehensive solutions covering dermatological medicines and medical-grade skincare products. Per Frost & Sullivan data, the Company secures the top position in China by the aggregate count of topical dermatological drugs that have been filed and granted marketing authorisations. Its commercial portfolio covers eight major dermatological indications across China, affecting approximately 843 million prevalent cases combined in 2025.

The Group has built a pipeline of more than 30 candidate assets, including three innovative drug candidates that have obtained IND approvals in China and three candidates completing pre-IND regulatory filings in the United States. Its product portfolio addresses scalp & hair disorders, facial conditions, trunk and extremity ailments as well as nail diseases across six core therapeutic areas.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

ZIYOND PHARMA IPO file a listing application